240 related articles for article (PubMed ID: 15161072)
21. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L
Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597
[TBL] [Abstract][Full Text] [Related]
22. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
23. Priming after a fractional dose of inactivated poliovirus vaccine.
Resik S; Tejeda A; Sutter RW; Diaz M; Sarmiento L; Alemañi N; Garcia G; Fonseca M; Hung LH; Kahn AL; Burton A; Landaverde JM; Aylward RB
N Engl J Med; 2013 Jan; 368(5):416-24. PubMed ID: 23363495
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).
Lang J; Cetre JC; Picot N; Lanta M; Briantais P; Vital S; Le Mener V; Lutsch C; Rotivel Y
Biologicals; 1998 Dec; 26(4):299-308. PubMed ID: 10403033
[TBL] [Abstract][Full Text] [Related]
25. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately.
Saenger R; Maechler G; Potreck M; Zepp F; Knuf M; Habermehl P; Schuerman L
Vaccine; 2005 Jan; 23(9):1135-43. PubMed ID: 15629356
[TBL] [Abstract][Full Text] [Related]
26. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age.
Nilsson L; Faldella G; Jacquet JM; Storsaeter J; Silfverdal SA; Ekholm L
Scand J Infect Dis; 2005; 37(3):221-9. PubMed ID: 15849057
[TBL] [Abstract][Full Text] [Related]
27. Development of inactivated poliovirus vaccine derived from Sabin strains.
Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of enhanced potency inactivated polio vaccine.
Singh J; Ravi RN; Dutta AK; Kumari S; Khare S
Indian Pediatr; 1992 Nov; 29(11):1353-6. PubMed ID: 1338200
[TBL] [Abstract][Full Text] [Related]
29. [The vaccine against poliomyelitis, inactivated, concentrated, injectable: analysis of ten years of use in tropical countries].
Drucker J
Bull Soc Pathol Exot; 1991; 84(5 Pt 5):866-72. PubMed ID: 1668069
[TBL] [Abstract][Full Text] [Related]
30. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
32. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.
Parkkali T; Stenvik M; Ruutu T; Hovi T; Volin L; Ruutu P
Bone Marrow Transplant; 1997 Oct; 20(8):663-8. PubMed ID: 9383230
[TBL] [Abstract][Full Text] [Related]
34. Response to immunization against polio after allogeneic marrow transplantation.
Ljungman P; Duraj V; Magnius L
Bone Marrow Transplant; 1991 Feb; 7(2):89-93. PubMed ID: 1646664
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on Vero cells or on primary monkey kidney cells.
Mallet L; Pelloquin F; Brigaud M; Caudrelier P; Bandet R; Xueref C; Fuchs F; Gibelin N; Goldman C; Moulin JC; de Fraipont F; Montagnon B; Peyron L; Aymard M
J Med Virol; 1997 May; 52(1):50-60. PubMed ID: 9131458
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
40. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
